A pharmacological and clinical review on the activity of a bovine factor VIIi derivative obtained by enzymatic hydrolysis
Ammannati, P.; Siravo, D.; Conte, B.
La Clinica Terapeutica 128(4): 271-290
1989
ISSN/ISBN: 0009-9074 PMID: 2524317 Document Number: 340719
We report pharmacological, experimental and clinical data of the new drug which decreases bleeding time but is devoid of procoagulant and platelet aggregating properties. The drug, derived from bovine factor VIII by enzymatic hydrolysis, did not show toxicological and immunological effects either in animals or in patients. In addition we report the review of the clinical studies in different pathological situations i.e. ophthalmology, odontostomatology, gynecology etc.
Document emailed within 1 workday
Related Documents
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Motuz, L.P.; Plotnikov, A.N.; Korotkov, K.V.; Alakhov, I.B. 1994: Structure-activity domain of elongation factor EF-2. Analysis of fragments of limited EF-2 hydrolysis, obtained using trypsin and elastase Bioorganicheskaia Khimiia 20(8-9): 872-882
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Zhukovskiĭ, I.G.; Kuznetsova, L.P.; Sochilina, E.E.; Veksler, K.V. 2004: Comparative study of enzymatic activity of cholinesterases of different origin in thionaphthylacetate hydrolysis reactions Ukrains'kyi Biokhimichnyi Zhurnal 76(5): 151-155
Szczodrak, J.; Rogalski, J.; Ilczuk, Z. 1984: Cellulolytic activity of moulds. III. Enzymatic hydrolysis of cellulose by cellulase preparation from Aspergillus terreus F-413 Acta Microbiologica Polonica 33(3-4): 207-216
Pencheva, T. 1977: Experimental and clinical data on the effect of various factors on enzymatic activity in surgical diseases (a review) Khirurgiia 30(6): 498-503
Klesov, A.A.; Grigorash, S.Iu. 1982: Enzymatic hydrolysis of cellulose. Regulatory effect of the non-soluble substrate on the effectiveness of the enzymatic reaction Biokhimiia 47(3): 409-418
Elykomov, V.A.; Tsalikhin, A.D. 1991: A uniform technique of one-stage factor VIII:C assay in cryoprecipitate and its concentrates. Part II (according to the results obtained by the group of the "Hemostasis Pathology Commission) Gematologiia i Transfuziologiia 36(11): 31-33
Rosén, S. 2001: A rebuttal: Issues with the assay of factor VIII activity in plasma and factor VII concentrates Thrombosis and Haemostasis 86(4): 1132-1133
Allain, J.P. 1972: Study of the "in vivo" activity of factor VIIi or factor IX after injection of several concentrates: practical applications Nouvelle Revue Francaise d'Hematologie 12(2): 241-249
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Lee, C.A.; Owens, D.; Bray, G.; Giangrande, P.; Collins, P.; Hay, C.; Gomperts, E.; Schroth, P.; Barrowcliffe, T. 1999: Pharmacokinetics of recombinant factor VIIi (recombinate) using one-stage clotting and chromogenic factor VIIi assay Thrombosis and Haemostasis 82(6): 1644-1647
Gatti, L.; Mannucci, P.M. 1984: Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies Thrombosis and Haemostasis 51(3): 379-384
Shibasaki, K.; Uchida, W.; Shirai, Y.; Inagaki, O.; Asano, M.; Takenaka, T. 1994: Pharmacological properties of YM-15430-1, a 1,4-dihydropyridine derivative with beta 1-adrenoceptor-blocking activity Archives Internationales de Pharmacodynamie et de Therapie 328(2): 213-224